BPC-157 vs BNP (B-type Natriuretic Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | BNP (B-type Natriuretic Peptide) |
|---|---|---|
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. |
| Best For |
What They Have in Common
Both BPC-157 and BNP (B-type Natriuretic Peptide) are commonly used for: